Biomerica is a global biomedical technology company that develops, patents, manufactures and markets diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Co.'s focus is the research and development of revolutionary, patented, diagnostic-guided therapy products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. Co. also develops, tests, validates, seeks regulatory approval for, and sells diagnostic products that indicate if a person has been infected by the 2019 SARS-CoV-2 novel coronavirus. The BMRA stock yearly return is shown above.
The yearly return on the BMRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BMRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|